menu
    • menu
    [{"orgOrder":0,"company":"Waterstone Pharmaceuticals Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"WS016","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Waterstone Pharmaceuticals Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Waterstone Pharmaceuticals Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Waterstone Pharmaceuticals Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Waterstone Pharmaceuticals Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"WS016","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Waterstone Pharmaceuticals Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Waterstone Pharmaceuticals Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Waterstone Pharmaceuticals Inc. \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Waterstone Pharmaceuticals Inc.

    Menu

    Waterstone Pharmaceuticals Inc.

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Waterstone Pharmaceuticals Inc.

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Waterstone Pharmaceuticals Inc.

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : WS016

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Safety and Tolerability of WS016 in Healthy Chinese Volunteers

                            Details : WS016 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hyperkalemia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 28, 2024

                            Lead Product(s) : WS016

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Waterstone Pharmaceuticals Inc.

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Waterstone Pharmaceuticals Inc.

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : WS016

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia.

                            Details : WS016 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hyperkalemia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 26, 2024

                            Lead Product(s) : WS016

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth